HVIVO PLC

Director's Dealing • Jun 2, 2025

National Storage Mechanism | Additional information

RNS Number : 9171K

hVIVO PLC

02 June 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

CEO & CFO Share Purchase

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin 'Mo' Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below:

Director	No of shares purchased	Purchase Price	Resultant holding	Resultant holding as a % of the issued share capital
Yamin 'Mo' Khan	1,100,000	8.9 pence	5,001,603	0.73%
Stephen Pinkerton	683,232*	8.76 pence	750,596*	0.11%

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton, wife of Stephen Pinkerton

Commenting, Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "Friday's trading update clearly raised concerns for our shareholders, but we remain confident in the continued growth of human challenge trials and the overall prospects for hVIVO, and accordingly Stephen and I have increased our shareholdings in the Company to demonstrate our continued confidence in the growth prospects of the Group.

"We have our largest ever sales pipeline, including projects under discussion that would represent some of our biggest ever value contracts for human challenge trials, such as the world's first ever Phase 3 HCT. We have also successfully targeted a more diversified revenue base and we remain very excited about the growth prospects of our hLAB services as well as our new revenue streams from CRS's early phase clinical trial services and participant recruitment."

For further information please contact:

hVIVO plc		+44 (0)20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				+44 (0)20 7220 0500
Geoff Nash, Callum Davidson, Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)			+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)			+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / Lianne Applegarth		+44 (0)20 7933 8780 or  hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654/ +44 (0)7584 391 303

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

Notes to Editors

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name of PDMR

Yamin Mo Khan

2

Reason for notification

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

hVIVO plc

b.

LEI

213800VT5KBM7JLIV118

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.001 each

ISIN GB00B9275X97

b.

Nature of the transaction

Purchase of Ordinary Shares

c.

Price(s) and volume(s)

No. of Shares	Price
1,100,000	8.9

d.

Aggregated information

- Aggregated Volume

- Price

See above

e.

Date of the transaction

30 May 2025

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name of PDMR

Stephen Pinkerton

2

Reason for notification

a.

Position/Status

Chief Financial Officer

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

hVIVO plc

b.

LEI

213800VT5KBM7JLIV118

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.001 each

ISIN GB00B9275X97

b.

Nature of the transaction

Purchase of Ordinary Shares

c.

Price(s) and volume(s)

No. of Shares	Price
683,232	8.76

d.

Aggregated information

- Aggregated Volume

- Price

See above

e.

Date of the transaction

30 May 2025

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBFLLBEQLFBBQ